GERN vs. ADCT
GERN (Geron Corporation) and ADCT (ADC Therapeutics SA) are both stocks. Both operate in the Biotechnology industry within the Healthcare sector. Over the past 5 years, GERN returned -2.34%/yr vs -45.89%/yr for ADCT. At a 0.32 correlation, their price movements are largely independent.
Performance
GERN vs. ADCT - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, GERN achieves a 2.27% return, which is significantly higher than ADCT's -67.42% return.
GERN
- 1D
- 0.75%
- 1M
- 5.47%
- YTD
- 2.27%
- 6M
- 1.50%
- 1Y
- -4.93%
- 3Y*
- -24.68%
- 5Y*
- -2.34%
- 10Y*
- -6.31%
ADCT
- 1D
- 5.50%
- 1M
- -66.08%
- YTD
- -67.42%
- 6M
- -67.14%
- 1Y
- -57.09%
- 3Y*
- -17.53%
- 5Y*
- -45.89%
- 10Y*
- —
GERN vs. ADCT - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|---|
GERN Geron Corporation | 2.27% | -62.71% | 67.77% | -12.81% | 98.36% | -23.27% | 12.77% |
ADCT ADC Therapeutics SA | -67.42% | 77.39% | 19.88% | -56.77% | -80.99% | -36.89% | 6.70% |
Correlation
The correlation between GERN and ADCT is 0.30, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.30 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.31 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.34 |
Correlation (All Time) Calculated using the full available price history since May 15, 2020 | 0.32 |
Fundamentals
GERN:
$903.66M
ADCT:
$177.26M
GERN:
-$0.10
ADCT:
-$0.99
GERN:
4.59
ADCT:
2.01
GERN:
$196.12M
ADCT:
$79.18M
GERN:
$119.67M
ADCT:
$71.82M
GERN:
-$40.62M
ADCT:
-$87.83M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
GERN vs. ADCT — Risk / Return Rank
GERN
ADCT
GERN vs. ADCT - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Geron Corporation (GERN) and ADC Therapeutics SA (ADCT). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| GERN | ADCT | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +0.55 | ||
| Sortino ratioReturn per unit of downside risk | +0.77 | ||
| Omega ratioGain probability vs. loss probability | 1.04 | 0.93 | +0.11 |
| Calmar ratioReturn relative to maximum drawdown | -0.11 | -0.72 | +0.60 |
| Martin ratioReturn relative to average drawdown | -0.24 | -2.40 | +2.15 |
Loading charts...
Drawdowns
GERN vs. ADCT - Drawdown Comparison
The maximum GERN drawdown since its inception was -98.73%, roughly equal to the maximum ADCT drawdown of -99.08%. Use the drawdown chart below to compare losses from any high point for GERN and ADCT.
Loading charts...
Drawdown Indicators
| GERN | ADCT | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -98.73% | -99.08% | +0.35% |
Max Drawdown (1Y)Largest decline over 1 year | -43.59% | -79.97% | +36.38% |
Max Drawdown (3Y)Largest decline over 3 years | -78.98% | -81.52% | +2.54% |
Max Drawdown (5Y)Largest decline over 5 years | -78.98% | -98.51% | +19.53% |
Max Drawdown (10Y)Largest decline over 10 years | -86.09% | — | — |
Current DrawdownCurrent decline from peak | -98.07% | -97.75% | -0.32% |
Average DrawdownAverage peak-to-trough decline | -86.17% | -77.46% | -8.71% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 20.31% | 23.83% | -3.52% |
Volatility
GERN vs. ADCT - Volatility Comparison
The current volatility for Geron Corporation (GERN) is 12.67%, while ADC Therapeutics SA (ADCT) has a volatility of 89.74%. This indicates that GERN experiences smaller price fluctuations and is considered to be less risky than ADCT based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| GERN | ADCT | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 12.67% | 89.74% | -77.07% |
Volatility (6M)Calculated over the trailing 6-month period | 46.29% | 97.72% | -51.43% |
Volatility (1Y)Calculated over the trailing 1-year period | 62.88% | 90.94% | -28.06% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 81.24% | 100.61% | -19.37% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 78.09% | 95.10% | -17.01% |
Dividends
GERN vs. ADCT - Dividend Comparison
Neither GERN nor ADCT has paid dividends to shareholders.
Financials
GERN vs. ADCT - Financials Comparison
This section allows you to compare key financial metrics between Geron Corporation and ADC Therapeutics SA. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
Frequently Asked Questions
GERN and ADCT have a correlation of 0.30, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
ADCT has higher volatility (89.74%) compared to GERN (12.67%). In terms of maximum drawdown, GERN dropped -98.73% vs ADCT's -99.08%.
GERN currently has the higher Sharpe Ratio (-0.08 vs -0.63), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for GERN and ADCT
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer